Last reviewed · How we verify
Claudin 18.2 CAR-T
Claudin 18.2 CAR-T is a Biologic drug developed by Suzhou Immunofoco Biotechnology Co., Ltd. It is currently in Phase 1 development. Also known as: IMC002.
At a glance
| Generic name | Claudin 18.2 CAR-T |
|---|---|
| Also known as | IMC002 |
| Sponsor | Suzhou Immunofoco Biotechnology Co., Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer (EARLY_PHASE1)
- Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma (PHASE1)
- A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients (PHASE3)
- Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors (PHASE1)
- Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer (PHASE1, PHASE2)
- Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection (PHASE1, PHASE2)
- Postoperative Adjuvant Therapy for CT041 Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Patients (PHASE1)
- Claudin18.2 CAR-T (CT041) in Patients with Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Claudin 18.2 CAR-T CI brief — competitive landscape report
- Claudin 18.2 CAR-T updates RSS · CI watch RSS
- Suzhou Immunofoco Biotechnology Co., Ltd portfolio CI
Frequently asked questions about Claudin 18.2 CAR-T
What is Claudin 18.2 CAR-T?
Claudin 18.2 CAR-T is a Biologic drug developed by Suzhou Immunofoco Biotechnology Co., Ltd.
Who makes Claudin 18.2 CAR-T?
Claudin 18.2 CAR-T is developed by Suzhou Immunofoco Biotechnology Co., Ltd (see full Suzhou Immunofoco Biotechnology Co., Ltd pipeline at /company/suzhou-immunofoco-biotechnology-co-ltd).
Is Claudin 18.2 CAR-T also known as anything else?
Claudin 18.2 CAR-T is also known as IMC002.
What development phase is Claudin 18.2 CAR-T in?
Claudin 18.2 CAR-T is in Phase 1.
Related
- Manufacturer: Suzhou Immunofoco Biotechnology Co., Ltd — full pipeline
- Also known as: IMC002
- Compare: Claudin 18.2 CAR-T vs similar drugs
- Pricing: Claudin 18.2 CAR-T cost, discount & access